ArticleBMC pediatrics2025
Comparison of demographic characteristics and haematological parameters in newborns with and without haemolytic disease due to ABO incompatibility.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ursodeoxycholic Acid in the Management of Prolonged Neonatal Hyperbilirubinemia: A Randomized Controlled Clinical Trial.Iranian journal of medical sciences · 2026Trial
- Pediatric ABO blood groups and disease distribution: a retrospective analysis.Translational pediatrics · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundABO incompatibility is the most common blood group incompatibility in newborn babies, haemolytic disease develops in very few cases and is much milder than Rh incompatibility. In our study, we aimed to retrospectively examine the changes in platelet parameters, in addition to the expected decrease in the erythrocyte count, in immunized ABO incompatible patients, by comparing them with those in the control group.
methodsThe demographic data and laboratory results of patients born in our hospital between November 1, 1997, and December 31, 2023, who had accessible information, were examined. The haemogram parameters of newborns with haemolytic disease who did not have ABO incompatibility those of newborns with ABO incompatibility and those of newborns with positive direct anti-globulin test results were compared using statistical methods.
resultsA total of 5,198 out of 7,780 newborns were included in the study. A total of 2582 newborns for whom demographic and laboratory values could not be obtained were excluded from the study. When the data of 5,158 newborns without incompatibility and 40 newborns with haemolytic disease due to ABO incompatibility were compared, the mean red blood cell (RBC), haematocrit, haemoglobin and mean platelet volume (MPV) values of newborns with haemolytic disease were found to be statistically significantly lower than those of newborns in the control group, whereas the platelet, mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC) and red cell distribution width (RDW) values were greater. Thrombocytopenia was not observed in any patient.
conclusionsHaemolytic disease due to ABO incompatibility is a mild haemolytic disease that is thought to be caused by maternal antibody density or low antigen density on neonatal erythrocytes. We detected an increase in the platelet count and a decrease in the erythrocyte count values in in the haemolytic group. Prospective studies are needed on this subject that also examine erythropoietin and thrombopoietin values.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.